Many senior executives of pharmaceutical companies quit or set off a battle for high-end professionals in the industry

[industry news of pharmaceutical network] recently, Ruikang pharmaceutical announced that the board of directors received the written resignation report of Ms Quan Yuhua, the independent director of the company, and Ms Quan Yuhua applied to resign from the position of independent director and relevant special committee of the company for personal reasons After resigning, she will no longer hold any position in the company In fact, in recent years, due to the influence of market and policy, the pharmaceutical industry has been updating and iterating At the beginning of 2020, many pharmaceutical companies have made structural adjustments and personnel changes to varying degrees It is understood that at least a dozen senior executives have left, and the specific author will not list them one by one In fact, the turnover trend started in 2019 According to data statistics, except for March, the number of executives leaving in other months of 2019 remained high In addition to domestic enterprises, as many as 45 senior managers of multinational pharmaceutical enterprises will leave in 2019, involving many well-known pharmaceutical enterprises such as AstraZeneca, Novartis, Lilly, Roche, Sanofi, BMS, GSK, etc In addition, data shows that since 2018, Pfizer, Sanofi, Novartis, GSK and other famous multinational pharmaceutical companies have cut nearly 20000 jobs globally In fact, although the pharmaceutical industry is known as the sunrise industry forever, and the pursuit of biotechnology and medical health in the capital market is second only to the it and Internet industries, but under the pressure of cost control, drug price reduction is gradually becoming a global trend In addition, the homogenization of drug research and development, the decline of return on investment of pharmaceutical enterprises, and the rising cost of developing new drugs are increasing the challenges to pharmaceutical enterprises In this environment, in order to develop pharmaceutical enterprises, marketing methods and management models need to be changed, so the resulting acceleration of talent flow is also conceivable Previously, the industry had predicted that personnel changes in the field of marketing will occur more frequently in 2020 So it's just the beginning for a large number of well-known pharmaceutical executives and marketing personnel to leave In the future, the flow of talents in the industry will continue In fact, despite the recent news of resignation in the industry, the turnover rate of medical personnel is not high compared with other industries According to a white list of market salary data for the first six months of 2019 from "salary intelligence" of Internet technology company, the overall turnover rate of the pharmaceutical industry is 5.91%, followed by 8.82% in the financial industry and 9.50% in the consumer goods industry In addition, compared with other industries, the salary of the pharmaceutical industry also keeps high growth at a high level Maybe the employment of the pharmaceutical industry is not perfect, but it is still one of the best employment options, especially the professional medical talents In general, with the continuous adjustment of national regulatory policies for the pharmaceutical industry, the strategy and layout of pharmaceutical enterprises should closely follow the policy changes, and the resulting talent adjustment is inevitable and sustainable In this form, pharmaceutical enterprises need to actively adjust the talent structure and build a new talent system according to the market development trend and their own needs In the future, the competitiveness of pharmaceutical enterprises will depend more on the competition of professional talents